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 Cardiovascular diseases and especially ischemic heart disease are the major cause 
of death in adults and among elderly patients in the developed and in many developing 
countries. The availability of invasive diagnostic and therapeutic procedures (coronary 
angiography, PTCA, stent implantation, CABG) is limited, mostly because of their 
excessive cost, thus the development of new agents for the treatment of ischemic heart 
disease is in the limelight of scientists.  
 The past decade has seen an explosion of knowledge regarding the role of 
oxidative stress in the pathogenesis of a wide variety of diseases, such as 
atherosclerosis, ischemia-reperfusion injury, cancer, chronic inflammation, autoimmune 
diseases and aging. 
 Sources of reactive oxygen species (ROS) in living cells are represented by 
physiological enzymatic mechanisms. They are generated from aerobic metabolism that 
utilizes life-sustaining oxygen to oxidize fuels. Mitochondria are well documented as a 
major source of O2.- and H2O2. Being major producers of ROS, mitochondrial structures 
are exposed to high concentrations of ROS and, therefore, are particularly susceptible to 
their attack. However various cytosolic and membrane bound oxidases and 
dehydrogenases (e.g. xanthine oxidase, lipoxygenase and NADH oxidase) are also 
known to produce free radicals.  
 Cells have developed various enzymatic and nonenzymatic systems against 
continuously generated free radicals to protect themselves from oxidative damages. 
Superoxide anions can be scavenged by superoxide dismutase, which catalyzes the 
conversion of two of these radicals into hydrogen peroxide and molecular oxygen: 
Hydrogen peroxide is scavenged by catalase that catalyzes the conversion of hydrogen 
peroxide into water and molecular oxygen. Peroxidases catalyze an analogous reaction 
in which hydrogen peroxide is reduced to water by a reductant (AH2): 
 Glutathione, which is present in high concentrations (5 mM) in animal cells, has a 
key role in detoxification by reacting with hydrogen peroxide and organic peroxides, 
and serves as a sulfhydryl buffer. Glutathione cycles between a reduced thiol form 
(GSH) and an oxidized form (GSSG). GSSG is reduced to GSH by glutathione 
reductase. 
 Other important physiological antioxidants are vitamin E and reduced coenzyme 
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Q (CoQ). Ascorbate and reduced glutathione are water-soluble antioxidants, which 
regenerate alfa-tocopherol. However, the protective effect of ascorbate and GSH against 
oxidative attack can attenuate or even reverse in the absence of vitamin E within the 
membranes. Physiological compounds, such as urate, bilirubin, and ceruloplasmin, can 
also protect against oxidative attack. 
 Despite of the complexity of the above mentioned antioxidant system, free 
radicals generated excessively in certain circumstances can break this barrier and cause 
an oxidative stress to the cell. In various forms of oxidative stress there are different 
sources of ROS. During ischemia-reperfusion, mitochondrial respiratory complexes, 
especially complex I, are the main sources of toxic oxygen intermediers. Hydrogen 
peroxide- or doxorubicine-induced oxidative injury in turn has at least two components. 
They can cause an enhanced mitochondrial ROS production, but their reaction with 
transition metals (e.g. Fe2+) inducing a site-specific oxyradical formation is also very 
important in the mediaton of oxidative cell injury. 
 Among the above-mentioned pathological states ischemia-reperfusion has the 
most pronounced importance. It has been clearly established that myocardial cells 
cannot survive under severe prolonged ischemia. Coronary reperfusion, therefore, 
appears to be the only appropriate therapeutic strategy. Early reperfusion may prevent 
or lessen the development of necrosis, but experimental studies have demonstrated that, 
in the meantime, it is accompanied by various characteristic disturbances, generally 
referred to as reperfusion injury.  
 Reactive oxygen species injure a wide variety of biomolecules and cell 
compartments. ROS initiate lipid peroxidation, protein oxidation and the formation of 
single-stranded DNA breaks. The major product of lipid peroxidation is 4-hydroxy-2-
nonenal, which is highly cytotoxic and can readily react with and damage proteins. 
Intracellular sodium and calcium accumulation is the consequence of the injury of ion 
channels and the decrease of myocardial high-energy phosphate levels. The high level 
of intracellular Ca2+ activates the proteolytic enzymes and it causes the conversion of 
xanthine dehydrogenase to xanthine oxidase. High intracellular Ca2+ level together with 
high intracellular inorganic phosphate concentration induces the opening of 
mitochondrial permeability transition pores (MPT pore). As a consequence of opening 
of the MPT pores, the mitochondrial membrane potential will collapse and the 
mitochondrial energy production will be ceased. Mitochondrial respiratory complexes 
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have a central role in the development of postischemic myocardial damage. They are 
the main sources of ROS during reoxygenation, but themselves are also injured by ROS 
and they exhibit a reduced activity during oxidative stress. The consequences are a 
decreased energy generation, an increased ROS production and eventually cell death. 
 ROS and NO-induced single-strand DNA break formation, on the other hand, 
activate the nuclear poly(ADP-ribose) polymerase (PARP). PARP enzyme is thought to 
play an essential role in different DNA related processes, such as replication, gene 
expression, and repair and maintenance of genomic stability. Upon activation, PARP 
cleaves NAD+ to nicotinamide and ADP-ribose which is coupled to different proteins 
and protein-bound ADP-ribose residues. Excessive PARP activation leads to cellular 
NAD+ and ATP depletion, which causes necrosis and inhibition of PARP can partially 
prevent ROS toxicity and ischemia-reperfusion-induced cell death. As a consequence, 
PARP inhibitors are widely used experimentally to protect cells from oxidative.  
 Oxygen free radical damage has been implicated in a wide range of diseases. 
Therefore, scavenging these radicals should be considered as an other basically 
important therapeutic approach. Antioxidant molecules and enzymes can potentially 
limit the oxidative injury but they are not readily internalized within myocardial cells, 
or they cannot reach the right cell compartment to exert their protective effect. 
Consequently, there is a long-standing effort to design small, non-toxic molecules, 
which can reach the right cell compartments and exhibit marked antioxidant properties 
against various types of oxidative injury.  
Small molecular weight, stable nitroxides have been shown to have potential 
therapeutic values in a variety of diseases, including myocardial reperfusion injury and 
doxorubicine-induced cardiotoxicity. Nitroxides are cell permeable, making it possible 
to provide both intracellular and extracellular protection against oxidative stress. It is 
important because ROS are highly reactive compounds with very short half-life time, so 
antioxidants must be at the right place at the time of the radical formation.  
Class I antiarrhythmic drugs are accumulating in the membrane of 
cardiomyocytes providing an ideal transport molecule for sterically hindered nitroxides 
and can improve their protective effect against myocardial oxidative stress.  
A group of pyrroline-based compounds has been shown to have a class I 
antiarrhythmic activity. The amino compound N-3-(2,2,5,5-tetramethyl-3-pyrroline-3-
carboxamido)propylphthalimide (H-2545) can be oxidized by mixed function amine 
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oxidases or ROS to form a stable nitroxide radical. This radical can be reduced by 
ascorbic acid to the N-hydroxyl form, which undergoes reversible one-electron 
oxidation to an N-oxyl compound. The N-oxyl molecule is sufficiently reactive to 
scavenge another ROS by transferring its hydrogen atom. 
 H-2545 has low toxicity, its therapeutical index is 8.8 in animals. Previous data 
showed that H-2545 could suppress the coronary-ligation-, digitalis- and adrenaline-
induced arrhythmias due to its effect on ion channels: H-2545 is a strong sodium 
channel blocker compound with a weak potassium and calcium channel blocking effect.  
 
 
2. OBJECTIVES OF THE STUDY 
 
2.1. ANTIOXIDANT COMPOUNDS 
 
 In our work we aimed to clarify what the lowest concentration is at which H-2545 
can offer a significant protection against oxidative myocardial injury. Previous data 
were obtained from experiments using H-2545 in high (50 μM) concentration in 
animals. 
 We have supposed that H-2545 is a superior scavenger molecule in myocardium 
compared to natural antioxidants because it accumulates in heart membranes and during 
its metabolism yields other molecules with marked antioxidant property. In addition, 
nitroxides, such as H-2545, have multiple actions against oxidative stress. Therefore, 
we compared the cardioprotective effect of H-2545 to the well-known antioxidant 
Trolox. 
 In various forms of oxidative stress the source of ROS is different. During 
ischemia-reperfusion ROS are dominantly derived from the mitochondrial respiratory 
chain. In the case of hydrogen peroxide or other externally administered oxidants there 
are at least two components. They also enhance the mitochondrial ROS formation but 
their damaging effect is mainly due to their reaction with transition metals (e.g. Fe2+) 
initiating a site-specific oxyradical formation. The effectiveness of H-2545 and its 
metabolite was examined both in ischemia-reperfusion and in hydrogen peroxide-
induced oxidative stress. 
We also strived for clarifying whether the cardioprotective effect of H-2545 can 
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be transferred to another drug accumulating in membranes (mexiletine), substituting it 
with a sterically hindered amine compound. 
 
2.2. PARP INHIBITORS 
 
It was reported previously that BGP-15, a new PARP inhibitor decreased the 
myocardial oxidative stress during ischemia-reperfusion. We wanted to test whether it 
was the specific effect of BGP-15 or it was a common feature of PARP inhibitors. 
The diminution of oxidative stress using BGP-15 was not due to a free radical 
scavenging effect. These data raise the possibility that PARP inhibitors may interfere 
with endogenous mitochondrial ROS formation by a different mechanism than 
antioxidants. We have compared the protective effect of PARP inhibitors on ischemia-
reperfusion and on hydrogen peroxide-induced lipid peroxidation. During reperfusion 
mitochondrium is the main source of ROS, however, in the case of hydrogen peroxide 
ROS are produced predominantly in site-specific reactions and just a small proportion 
of them are derived from the mitochondria.  
We aimed to investigate whether the influence of PARP inhibitors on the 
endogenous mitochondrial ROS formation can be attributed to a direct mitochondrial 
effect of these compounds, or it is an indirect effect due to altered NAD catabolism and 
high-energy metabolism. Therefore, protective effect of PARP inhibitors against 
hydrogen peroxide-induced oxidative injury were studied in isolated mitochondria. 
Finally, we intended to examine whether the PARP inhibiting moiety of the 
compounds, or another common chemical structure is essential for the direct 
mitochondrial protective effect. 
 
 
3. MATERIALS AND METHODS  
 
3.1. Chemicals 
The synthesis of H-2545 and H-2954 has already been published. Mexiletine, 
Trolox, 3-aminobenzamide, 3-aminobenzoic acid, 4-hydroxyquinazoline, nicotinamide 
were purchased from Sigma - Aldrich Chemical Co. (Budapest, Hungary). BGP-15 was a 
gift from N-Gene Research Laboratories, Inc. (Budapest, Hungary). All other reagents 
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were of the highest purity commercially available. 
 
3.2. Animals 
 The hearts of adult male Wistar rats weighing 300-350 g were used for the 
Langendorff heart perfusion experiments. The investigation conforms to the Guide for the 
Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication NO. 85-23, revised 1996), and approved by the Animal Research 
Review Committee of the University of Pecs Medical School. 
 
3.3. Heart perfusion  
 Rats were anesthetized with ketamine and heparinized. Hearts were perfused 
according to the Langendorff method at a constant pressure of 70 mmHg, at 37oC. The 
perfusion medium was a modified phosphate-free Krebs-Henseleit buffer consisting of 118 
mM NaCl, 5 mM KCl, 1.25 mM CaCl2, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose 
and 0.6 mM octanoic acid. In treated groups, perfusion medium additionally contained 
antioxidants (H-2545, H-2954, mexiletine, HO-2434 or HO-2433) in 10 µM concentration 
or PARP inhibitors (3 mM nicotinamide, 3 mM 3-aminobenzamide, 100 μM 4-
hydroxyquinazoline or 40 mg/l = 113,9 μM BGP-15) or 3-aminobenzoic acid (3 mM). 
The perfusate was adjusted to pH 7.40 and bubbled with 95% O2/ 5% CO2 through a glass 
oxygenator. 
3.3.1. Ischemia-reperfusion  
 After a washout, non-recirculating period of 15 minutes, hearts were either perfused 
under normoxic conditions for the given time, or were subjected to a global ischemia of 45 
or 25 minutes by closing the aortic influx and reperfused for 15 or 30 minutes. During 
ischemia hearts were submerged into perfusion buffer at 37oC. At the end of perfusion 
hearts were freeze clamped. 
3.3.2. Perfusion with hydrogen peroxide 
 Hearts were perfused after the washout period with or without 0.5 mM hydrogen 
peroxide and, in treated groups, in the presence of a scavenger or a PARP inhibitor 
compounds for 30 min.  
 
 
3.4. Determination of heart function 
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 A latex balloon was inserted into the left ventricle through the mitral valve and 
filled to achieve an end-diastolic pressure of 8-12 mmHg. All measurements were 
performed at the same balloon volume. The length of normoxia, ischemia and reperfusion 
were 15, 25, 45 min, respectively. Functional data of rat hearts (LVDP - left ventricle 
developed pressure, RPP - rate-pressure product, HR – heart rate, and dP/dt) were 
monitored during the perfusion. 
 
3.5. Assessment of cell membrane integrity 
 Release of lactate dehydrogenase EC 1.1.1.27 (LDH), creatine kinase EC 2.7.3.2 
(CK) and aspartate aminotransferase EC 2.6.1.1 (AST) enzymes were measured in the 
perfusate of Langendorff perfused hearts under normoxic and postischemic conditions. 
Enzyme activities were measured by standard methods as described in for LDH, for 
AST and for CK. 
 
3.6. Lipid peroxidation  
 Lipid peroxidation was estimated from the formation of thiobarbituric acid reactive 
substances (TBARS). Cardiac tissue was homogenized in 6.5 % trichloroacetic acid (TCA) 
and a reagent containing 15% TCA, 0.375 % thiobarbituric acid (TBA) and 0.25 % HCl 
was added, mixed thoroughly, heated for 15 min in a boiling water bath, cooled, 
centrifuged and the absorbency of the supernatant was measured at 535 nm against a blank 
that contained all the reagents except the tissue homogenate. Using MDA standard TBARS 
were calculated as nmoles/g wet tissue. 
 
3.7. Determination of protein carbonyl content  
 Fifty mg of freeze-clamped perfused heart tissue were homogenized with 1 ml 4% 
perchloric acid and the protein content was collected by centrifugation. The protein 
carbonyl content was determined by the 2,4-dinitrophenylhydrazine-method. 
 
3.8. Determination of DNA single-strand breaks 
 Single-strand DNA breaks were determined by the alkaline fluorescence analysis of 
DNA unwinding as described before by Javcek and Birnboim.  
 
3.9. Assay of NAD+
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 The concentration of NAD+ in the neutralized perchloric acid extract of the 
cardiac muscle was measured by using alcohol dehydrogenase reaction. The freshly 
prepared reaction buffer contained 0.1M Tris, pH 8.40, 1 mM EDTA, 4 mM L-cysteine 
chloride and 2% ethanol. Each cuvette contained 300 μl of the tissue extract, 650 μl of 
the reaction buffer and 4 units enzyme. The reaction was initiated by the addition of the 
enzyme and the exact tissue NAD+ concentrations were determined from a calibration 
curve. 
 
3.10. Direct scavenger effect of antioxidant compounds 
 Reactive oxygen species (ROS) formation was detected using the oxidation-sensitive 
non-fluorescent probe dihydrorhodamine 123 (DHR) which can be oxidized by ROS to 
fluorescent rhodamine 123. Rhodamine 123 content was determined in the suspension of 
mitochondrial inner membrane by a Perkin Elmer fluorescence spectroscope at an 
excitation wavelength of 496 nm and an emission wavelength of 536 nm. Mitochondrial 
inner membrane was suspended in 2 ml 20 mM Tris buffer pH 7.40 containing 150 mM 
KCl, 2 mM succinate, 8 μM antimycine A, 1 μM dihydrorhodamine 123 and, in some 
experiment, 1 mM sodium nitroprusside.  
 Antioxidant effect of H-2545 and H-2954 were also studied in an another system 
where hydroxyl radicals were generated in Fenton reaction and the hydroxylation of 
benzoic acid was used to follow the hydroxyl radical reaction fluorimetrically. The reaction 
took place in 20 mM sodium phosphate, pH 6.8, containing 100 μM benzoic acid, 100 
μM H2O2, 10 μM Fe2+-EDTA. Fluorescence was detected at an excitation wavelength 
of 305 nm and an emission wavelength of 407 nm. 
 
3.11. Determination of mitochondrial ROS production 
 Mitochondria were incubated in a buffer containing 150 mM KCl, 1 mM EDTA, 
5 mM MOPS, 1 mM succinate at pH 7.4 and in the presence of PARP inhibitors and 3-
aminobenzoic acid (0.2, 1, 3 mM). Mitochondrial suspension was stirred and after the 
addition of hydrogen peroxide (final concentration 1 mM), ROS production was 
continuously monitored by following the oxidation of DHR to rhodamine123 in a 
Perkin Elmer fluorescence spectroscope at an excitation wavelength of 496 nm and an 
emission wavelength of 536 nm. 
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3.12. Isolation of mitochondria and mitochondrial inner membrane 
 Mitochondria and inner mitochondrial membrane vesicles were isolated from 
sacrificed or perfused rat hearts as described before and were stored in 5 mM MOPS pH 
7.4, 150 mM KCl and 1 mM EDTA. 
 
3.13. Measurement of mitochondrial enzyme activity 
 Citrate synthase, NADH: cytochrome c oxidoreductase and cytochrome oxidase 
activities were measured as described previously. 
 
3.14. NMR spectroscopy 
 NMR spectra were recorded with a Varian UNITYINOVA 400 WB instrument 
(Varian Inc., Palo Alto, CA, USA). 
 31P measurements (161.90 MHz) of perfused hearts were run at 37°C in a 
Z•SPEC® 20 mm broadband probe (Nalorac Co., Martinez, CA, USA), applying 
GARP-1 proton decoupling (γB2=1.2 kHz) during acquisition. Field homogeneity was 
adjusted by following the 1H signal (w1/2=10-15 Hz). Spectra were collected with a 
time resolution of 3 min by accumulating 120 transients in each FID. 45° flip angle 
pulses were employed after a 1.25 s recycle delay, and transients were acquired over a 
10 kHz spectral width in 0.25 s, and the acquired data points (5000) were zero-filled to 
16K.  
 Under the above circumstances, the relative concentrations of the species can be 
taken proportional to the peak areas, since interpulse delays exceeded 4-5×T1 values of 
the metabolites to be analyzed in 31P experiments. 
 
3.15. Statistical Analysis 
 Statistical analysis was performed by ANOVA and all of the data were expressed 
as the mean ± S.E.M. Significant differences were evaluated by use of unpaired 






4.1. ANTIOXIDANT COMPOUNDS 
 
H-2545 in the concentration of 10 μM decreased efficiently the ischemia-reperfusion 
induced leakage of intracellular enzymes (CK, AST, LDH) into the coronary effluent (1). 
Similarly lipid peroxidation (2), protein oxidation (3) and ssDNA break formation (4) were 
also decreased by H-2545 in postischemic myocardium. During reperfusion due to the 
formation of ssDNA breaks, an increased NAD+ catabolism could be observed, which can 
be prevented by using H-2545 (5). Furthermore H-2545 decreased the partial inactivation 
of mitochondrial respiratory complexes during reoxygenation (6).  
Due to the decreased NAD+ catabolism and improved mitochondrial function H-
2545 improved the recovery of high-energy phosphates (PCr, ATP) in postischemic hearts 
in comparison with untreated hearts (7). Recovery of myocardial pH was also much more 
pronounced in treated hearts (8). Consumption rate of Pi was increased and quite complete 
in postischemic hearts treated with H-2545, compared to 50% reutilization measured in 
untreated hearts (9).  
In line with the faster and more complete utilization of inorganic phosphate, an 
improved functional recovery of rat hearts during reperfusion was seen in H-2545 treated 
group compared to untreated hearts (10). Although, H-2545 and H-2954 are equally 
effective scavengers of hydroxyl radicals (11), H-2954 had a significantly higher ability to 
scavenge superoxide anions than H-2545 (12). Despite of this, H-2954 caused a 
significantly lower protection against the ischemia-reoxygenation induced myocardial 
injury compared to that of H-2545 (13).  
Comparing the cardioprotective effect of H-2545, H-2954 and Trolox, H-2954 and 
Trolox have similar protective effect against the impairment of postischemic energy 
metabolism, at the same time H-2545 exerts significantly greater protection against 
oxidative myocardial injury than Trolox (14). H-2545 was effective not only against 
ischemia-reperfusion-induced myocardial damage but also against hydrogen peroxide-
induced cell injury, a phenomenon that derives in part from its scavenging capacity but also 
from the ability to oxidate redox active metals and as so hindering the Fenton reaction (15).  
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The substitution of mexiletine with a 2,2,5,5-tetramethyl-pyrroline group improved 
the cardioprotective effect of the compound and yielded a similarly efficacious drug as H-
2545 in preventing postischemic myocardial damage (16). Thus, the sterically hindered 
pyrroline-ring is responsible for the cardioprotectivity of H-2545 and substitution of drugs 
accumulating in membranes with a pyrroline ring or with other nitroxide precursors can 
yield effective scavenger molecules.  
This type of antiarrhythmic-antioxidant therapy can be a conceptionally new, highly 
effective treatment in preventing postischemic or drug-induced oxidative damages. 
 
4.2. PARP INHIBITORS 
 
Our data showed that not only BGP-15 but all of the investigated PARP inhibitors 
decreased the oxidative injury in postischemic rat hearts (1). PARP inhibitors abrogated 
ischemia-reperfusion induced lipid peroxidation (2) and protein oxidation (3) and 
significantly decreased ssDNA break formation (4).  
In case the oxidant was given to the heart externally (H2O2), PARP inhibitors only 
partially protected the heart tissue from lipid peroxidation and protein oxidation (5). 
Therefore, PARP inhibitors decreased ischemia-reperfusion-induced increase of 
mitochondrial ROS production and, consequently, all oxidative damages related to 
enhanced ROS production (6). The observation that PARP inhibitors prevent ischemia-
reperfusion induced inactivation of respiratory complexes (7) supports this argument.  
PARP inhibitors decreased ischemia-reperfusion induced NAD+ (8) depletion and 
uniformly promoted the recovery of ATP and creatine phosphate levels (9) and resulted not 
only in higher percentage of recovery but the rate of recovery was also significantly faster. 
In addition, the consumption rate of inorganic phosphate was increased (10) during the 
recovery period by PARP inhibitors.  
The studied PARP inhibitors, beside their primary effect of inhibiting the activity of 
nuclear PARP and, therefore, decreasing NAD+ and ATP consumption, protect 
mitochondrial energy metabolism (11), decrease the ischemia-reperfusion induced 
mitochondrial ROS formation (12) and protect the respiratory complexes from ROS 
induced inactivation (13). However, 3-aminobenzoic acid, which is a chemical analog of 3-
amino-benzamide without any PARP inhibitory effect, was ineffective in the same 
experimental system (14).  
 12
The mitochondrial protective effect of PARP inhibitors, at least partially, is 
independent of nuclear PARP activity because it can be observed in isolated mitochondria 
(15), as well. Therefore, it represents a novel mechanism for the mitochondrial protective 
effects of PARP inhibitors. 
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